Abstract
Nephropathy is one of the major complications of diabetes which further directs to end stage renal disease. Extensive work has been done to find out the mechanisms involved in pathogenesis of the DN. Now, many researchers have been convinced that almost all of the molecular mediators and intracellular signaling pathways involved in progression of diabetic nephropathy have involvement in transforming growth factor beta (TGF- β) at some stage.
In DN, hyperglycemia causes increase in the expression of TGF- β genes, TGF- β proteins and their receptors. Increased glucose level mediates these effects through activation of polyol pathway, protein kinase C pathway, hexosamine pathway, increases advanced glycation end products (AGE) and increases oxidative stress. Hyperglycemia also activates the TGF- β via activation of glucose transporters (GLUT), angiotensine II and platelet derived growth factor (PDGF). Activated TGF-β further leads to glomerular basement membrane (GBM) thickening and glomerulosclerosis through activation of connective tissue growth factor (CDGF) and vascular endothelial growth factor (VEGF).
We have discussed the progression of hyperglycemia to DN via TGF- β, whose schematic presentation may serve as an effective way to understand the mechanisms and to find out an effective way for the management of diabetic nephropathy.
Keywords: AGE, GBM, glomerulosclerosis, PDGF, protein kinase C, VEGF.
Current Diabetes Reviews
Title:Hyperglycemia to Nephropathy via Transforming Growth Factor Beta
Volume: 10 Issue: 3
Author(s): Mayuresh Sudamrao Garud and Yogesh Anant Kulkarni
Affiliation:
Keywords: AGE, GBM, glomerulosclerosis, PDGF, protein kinase C, VEGF.
Abstract: Nephropathy is one of the major complications of diabetes which further directs to end stage renal disease. Extensive work has been done to find out the mechanisms involved in pathogenesis of the DN. Now, many researchers have been convinced that almost all of the molecular mediators and intracellular signaling pathways involved in progression of diabetic nephropathy have involvement in transforming growth factor beta (TGF- β) at some stage.
In DN, hyperglycemia causes increase in the expression of TGF- β genes, TGF- β proteins and their receptors. Increased glucose level mediates these effects through activation of polyol pathway, protein kinase C pathway, hexosamine pathway, increases advanced glycation end products (AGE) and increases oxidative stress. Hyperglycemia also activates the TGF- β via activation of glucose transporters (GLUT), angiotensine II and platelet derived growth factor (PDGF). Activated TGF-β further leads to glomerular basement membrane (GBM) thickening and glomerulosclerosis through activation of connective tissue growth factor (CDGF) and vascular endothelial growth factor (VEGF).
We have discussed the progression of hyperglycemia to DN via TGF- β, whose schematic presentation may serve as an effective way to understand the mechanisms and to find out an effective way for the management of diabetic nephropathy.
Export Options
About this article
Cite this article as:
Garud Sudamrao Mayuresh and Kulkarni Anant Yogesh, Hyperglycemia to Nephropathy via Transforming Growth Factor Beta, Current Diabetes Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/1573399810666140606103645
DOI https://dx.doi.org/10.2174/1573399810666140606103645 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circadian Variation of Cardiovascular Events and Morning Blood Pressure Surge
Vascular Disease Prevention (Discontinued) The GSTM1 and GSTT1 Null Genotypes Increase the Risk for Type 2 Diabetes Mellitus and the Subsequent Development of Diabetic Complications: A Meta-analysis
Current Diabetes Reviews An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Synthesis and Biological Activity of Nitric Oxide-releasing Derivatives of Ferulic Acid as Potential Agents for the Treatment of Chronic Kidney Diseases
Medicinal Chemistry Fc-fusion Proteins in Therapy: An Updated View
Current Medicinal Chemistry RAGE, Diabetes, and the Nervous System
Current Molecular Medicine Research Advances of Endostatin and its Short Internal Fragments
Current Protein & Peptide Science Vitamins and Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued) Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Diabetic Vascular Dysfunction
Current Vascular Pharmacology Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design Editorial (Thematic Issue: Aging and Metabolic Syndrome: Common Molecular Pathways)
Current Diabetes Reviews Renoprotection and Mechanisms of Erythropoietin and Its Derivatives Helix B Surface Peptide in Kidney Injuries
Current Protein & Peptide Science Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Current Cardiology Reviews Antidiabetic Drugs and the Kidney
Current Pharmaceutical Design Potential Role of Rho Kinase Inhibitors in Combating Diabetes-Related Complications Including Diabetic Neuropathy-A Review
Current Diabetes Reviews Application of Carbon Monoxide for Transplantation
Current Pharmaceutical Biotechnology Asymmetric Dimethylarginine (ADMA) and Cardiovascular Disease
Vascular Disease Prevention (Discontinued)